Facebook Twitter Instagram
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Facebook Twitter Instagram
    Pharmacognosy Communications
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Pharmacognosy Communications
    retyeyutreu
    Original Article

    Aleurites moluccanus (l.) Willd. Extracts Inhibit the Growth of Bacterial Triggers of Selected Autoimmune Inflammatory Diseases

    wadmin2By wadmin2May 6, 2017Updated:August 12, 2021No Comments2 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Share
    Facebook Twitter LinkedIn WhatsApp Pinterest Email

    Lindiwe Nomathemba Mpala1, Getmore Rumbudzai Chikowe1, Ian Edwin Cock1,2*
    1School of Natural Sciences, Nathan Campus, Griffith University, 170 Kessels Rd, Nathan, Brisbane, Queensland 4111, Australia.
    2Environmental Futures Research Institute, Nathan Campus, Griffith University, 170 Kessels Rd, Nathan, Brisbane, Queensland 4111, Australia.

    Pharmacognosy Communications,2017,7,2,83-90.
    DOI:10.5530/pc.2017.2.12
    Published: May 2017
    Type: Original Article

    ABSTRACT

    Introduction: Aleurites moluccanus (L.) Willd. is a large tree with a wide global distribution. All parts of the tree have been used medicinally and the nut is consumed in a variety of cuisines. Despite this, A. moluccanus nut extracts have not been rigorously examined growth inhibitory properties against many bacteria, including the bacterial triggers of autoimmune inflammatory diseases. Methods: The antimicrobial activity of A. moluccanus nut solvent extractions was investigated by disc diffusion and growth time course assays against a panel of bacterial triggers of autoimmune diseases. The growth inhibitory activity was further quantified by MIC determination. Toxicity was determined using the Artemia franciscana nauplii bioassay. Results: Methanolic and aqueous A. moluccanus nut solvent extracts were potent inhibitors of all of the bacterial triggers of autoimmune diseases screened in this study. The methanolic extract displayed the most potent bacterial growth inhibitory activity. It was particularly potent against the bacterial triggers of rheumatoid arthritis (MICs of 438 and 215 μg/mL against reference and clinical Proteus mirabilis strains; MIC of 187 μg/mL against Proteus vulgaris). The methanolic extract was also a good inhibitor of K. pneumoniae and S. pyogenes growth with MICs < 1000 μg/mL. The aqueous and ethyl acetate extracts were also potent bacterial growth inhibitors, albeit with slightly higher MIC values. The antibacterial activity of the methanolic and aqueous A. moluccanus nut extracts were further investigated by growth time course assays which showed significant growth inhibition in cultures of P. mirabilis, K. pneumpniae and S. pyogenes within 1 h of exposure. All extracts were determined to be nontoxic in the Artemia franciscana nauplii bioassay, indicating their safety for prophylactic use in preventing these autoimmune inflammatory diseases. Conclusions: The lack of toxicity of the A. moluccanus nut extracts and their growth inhibitory bioactivity against the bacterial triggers of rheumatoid arthritis, ankylosing spondylitis and rheumatic heart disease indicate their potential in the development of new therapies targeting the onset of these diseases.

    Key words: Euphorbiaceae, Candlenut, Rheumatoid Arthritis, Ankylosing Spondylitis, Rheumatic Heart Disease, Antibacterial Activity, Medicinal Plants.

    Download PDF
    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    About Journal
    About Journal

    Pharmacognosy Communications [Phcog Commn.] is a quarterly journal published by Phcog.Net. It is a peer reviewed journal aiming to publish high quality original research articles, methods, techniques and evaluation reports, critical reviews, short communications, commentaries and editorials of all aspects of medicinal plant research. The journal is aimed at a broad readership, publishing articles on all aspects of pharmacognosy, and related fields. The journal aims to increase understanding of pharmacognosy as well as to direct and foster further research through the dissemination of scientific information by the publication of manuscripts. The submission of original contributions in all areas of pharmacognosy are welcome.
    Indexed and Abstracted in : Chemical Abstracts, Excerpta Medica / EMBASE, Google Scholar, CABI Full Text, Ulrich’s International Periodical Directory, ProQuest, Journalseek & Genamics, PhcogBase, EBSCOHost, Academic Search Complete, Open J-Gate, SciACCESS.
    Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online publication is 45 days.
    Open Access Journal: Phcog Commn. is an open access journal, which allows authors to fund their article to be open access from publication.

    © 2025 Pharmacognosy Communications. Maintained by Manuscript TechnoMedia LLP.

    Type above and press Enter to search. Press Esc to cancel.

    Scroll Up